

MAR. 3. 2004 4:59PM NEEDLE & ROSENBERG

NO. 2965 P. 1

RECEIVED
CENTRAL FAX CENTER

MAR 03 2004

NEEDLE & ROSENBERG

OFFICIAL

IMPORTANT FAX DOCUMENT

NEEDLE & ROSENBERG PC
SUITE 1000
999 PEACHTREE STREET
ATLANTA, GEORGIA 30309-3915
678-420-9300
NEEDLERROSENBERG.COM

DATE March 3, 2004
NAME Examiner Myron G. Hill
COMPANY U.S. Patent and Trademark Office
FAX NUMBER (703) 308-4242

FROM Teresa R. Spratt for Gwendolyn D. Spratt
REFERENCE NO. 14114.0331U2
OUR FAX NUMBER 678-420-9301
NUMBER OF PAGES 6

In re Application of

Switzer et al.

Application No. 10/018,627

Filed: March 3, 2003

For: "ISOLATION OF A HUMAN
RETROVIRUS"

Group Art Unit: 1648

Examiner: Hill, Myron G.

Confirmation No. 5188

CONFIDENTIALITY NOTE

The information which follows and is transmitted herewith is attorney privileged, trade secret and confidential information intended only for viewing and use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any review, use, communication, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address.

MAR. 3. 2004 4:59PM

NEEDLE & ROSENBERG

NO. 2965 **RECEIVED**
P. 2
CENTRAL FAX CENTER

MAR 03 2004

ATTORNEY DOCKET NO. 14114.0331U2
PATENT

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Switzer et al.

Application No. 10/018,627

Filed: March 3, 2003

FOR: "ISOLATION OF A HUMAN RETROVIRUS"

Group Art Unit: 1648

Examiner: Hill, Myron G.

Confirmation No. 5188

RESPONSE TO OFFICE ACTION

VIA FACSIMILE 703/308-4242

ATTN: Examiner M. Hill
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

Sir:

This Amendment and Response to Office Action filed under 37 C.F.R. § 1.113 is responsive to the Office Action dated December 16, 2003 issued regarding the above-referenced patent application.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this response.

Remarks begin on page 4 of this response.